No Data
No Data
Pulling Back 4.4% This Week, Ligand Pharmaceuticals' NASDAQ:LGND) One-year Decline in Earnings May Be Coming Into Investors Focus
Express News | Ligand Pharmaceuticals - Following Engagement With FDA, Co Expects to Submit an Snda for Potential Modification to Liver-Monitoring Rems
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI (Sparsentan), the Only Non-Immunosuppressive Treatment That Significantly Slows Kidney Function Decline in IgA Nephropathy
Express News | Ligand Partner Travere Therapeutics Receives Full FDA Approval for Filspari® (Sparsentan), the Only Non-Immunosuppressive Treatment That Significantly Slows Kidney Function Decline in Iga Nephropathy
Travere Gains on Full FDA Approval for Kidney Drug Filspari
Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference